SFM
ACAD icon

Sphera Funds Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Sphera Funds Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-80,000
Closed -$2.24M – 93
2016
Q1 		$2.24M Buy
+80,000
New +$1.74M 0.48% 41

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sphera Funds Management's ACAD Position: Q2 2026 in Review

Sphera Funds Management increased its Acadia Pharmaceuticals (ACAD) stake by 39% in Q2 2026, buying an estimated $2.21M and bringing the position to 356,534 shares worth $9.02M. The position accounts for 1.18% of the portfolio, ranked #22.

Sphera Funds Management first reported a position in ACAD in Q4 2013 and has held it in 17 quarters since. The position peaked at $15.3M in Q4 2019. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Sphera Funds Management held 356,534 shares of Acadia Pharmaceuticals worth $9.02M as of Q2 2026.
  • Sphera Funds Management bought 100,332 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.21M.
  • Acadia Pharmaceuticals made up 1.18% of Sphera Funds Management's portfolio in Q2 2026, its #22 holding.
  • Sphera Funds Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 17 quarters since.
  • Sphera Funds Management's Acadia Pharmaceuticals position peaked at $15.3M in Q4 2019.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.